Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Authors :: Nancy L. Bartlett
Laurie H. Sehn
Matthew J. Matasar
Stephen J. Schuster
Sarit Assouline
Pratyush Giri
John Kuruvilla
Miguel Canales
Sascha Dietrich
Keith Fay
Matthew Ku
Loretta J. Nastoupil
Michael C. Wei
Shen Yin
Iris To
Huang Huang
Juliana Min
Elicia Penuel
L. Elizabeth Budde
Source :: Blood. 140:1467-1470
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Full Text Access

Tools